CRYOPORT, INC. Debt Securities, Available-for-sale, Amortized Cost
CRYOPORT, INC. (CYRX) had Debt Securities, Available-for-sale, Amortized Cost of $373.56 million as of 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2022-05-05
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $373.56M.
- 2021-12-31: Debt Securities, Available-for-sale, Amortized Cost $383.55K; Debt Securities, Available-for-sale, Amortized Cost as first filed $383.55M.
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost $197.15M.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $230.14M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2022-03-31 | $373.56M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $383.55K 10-Q · filed 2022-05-05 | $383.55M 10-K · filed 2022-02-28 |
| 2021-09-30 | $197.15M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $230.14M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $235.19M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $23.18M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $26.22M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $149.23M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $32.23M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $21.12M 10-K · filed 2021-03-01 | $21.12M 10-K · filed 2020-03-10 |
| 2019-09-30 | $23.10M 10-Q · filed 2019-11-12 | |
| 2018-12-31 | $7.90M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |